Genetronics Biomedical Ltd.

Founded in 1983, Genetronics is a San Diego-based drug delivery company specializing in developing technology and hardware which potentially will allow physicians more efficiently and cost-effectively to deliver life-saving drugs or beneficial genes to patients with catastrophic illnesses, including cancer and heart disease. Genetronics is the technology leader in electroporation, the application of very brief, carefully controlled, pulsed, rotating electric fields to human cells, a process that causes pores to open in the cell membrane and allows pharmaceuticals or genes to gain access to the cell's interior. The Company has a strong patent portfolio of 185 patents approved or pending, a formidable barrier to competition.

Electroporation is a broad-based technology, with many ways to achieve commercial success. Genetronics is developing applications for this technology in the primary areas of oncology and gene therapy, with additional research in dermatology, cardiology and transdermal drug delivery. The market for each of these applications of its core technology of electroporation is over $1 billion, and Genetronics' technology has shown feasibility in each area.